Categories
News

NeoTX Interview – Geektime.com

Curing cancer is no small feat: Israel’s NeoTX is still up for the challenge.

The startup’s CEO sits down with Geektime for an exclusive interview about how he and his team at NeoTX are changing the biopharmaceutical industry
By Alissa Abrahami / 3 Aug 2022 

Israeli startup NeoTX is a biopharmaceutical company that focuses on research and development in the field of oncology. Founded in 2015, NeoTX developed a Tumor Targeted Superantigen (TTS) platform technology which was inspired by the fact that the immune system is much better at killing bacteria than cancer cells. The TTS has two components: a TAA (Tumor Associated Antigen) which is a molecule that attaches to cancer cells and a Superantigen Peptide which can activate a controlled, natural, antibacterial immune response. What the TTS does, gis it coats the tumour with a superantigen (bacteria) and lets the body’s immune system do the work; the immune system attacks the bacteria and subsequently the tumour it surrounds. This ultimately converts a weak antitumoral immune response to a strong, antibacterial one, and has even worked in patients who are not responding to their standard immunotherapy treatment. TTS technology has the potential to challenge the effectiveness of other cancer treatments such as chemotherapy and CAR-T cell therapy, as the advantage of TTS that is not seen in chemotherapy, is that the immune system is used to attack cancerous tumours that develop alongside the disease and provides an active response to the development of the tumour.

We sat down with Asher Nathan, one of NeoTX’s co-founders, and CEO, to better understand the journey that brought him and NeoTX to where they are today.

Nathan is a Chicagoan who moved to Israel many years ago. He started his career at the University of Illinois where he received a BSc in chemistry and biology. He then continued his studies at The Hebrew University of Jerusalem. Since completing his education, he has had an impressive track record in the field of biotechnology; he was Managing Director at Paramount Biocapital, drug development and investment firm; founded IntelliGenne and EvoRx, two biotech companies; and served as a Managing Partner at Zoticon Bioventures, a company he co-founded. His career has led him to gain extensive experience in biotechnology, business strategy and development, and entrepreneurship. Moreover, he has authored over 25 patents in the biotechnology field.

Fighting the big fight

Though Nathan has dabbled in other specialties within biotech, he has gravitated toward oncology: “Oncology has always been closest to my heart. I love the challenge. I compare it to the lure of a casino. What we are setting out to do looks easy – kill the out-of-control cancer cells without killing the healthy cells– yet no matter what you throw at them, they appear more intelligent and evolve resistance faster than we can develop new drugs.” It is this challenge that drives Nathan every day. He has two strategies for running NeoTX and that is to think differently and think big. He explained to us that to overcome such a daunting task, such as killing cancer cells, you need to have a different approach than all the other biotech companies striving to achieve the same thing. “It is nearly impossible to have a unique drug in immune oncology. It is a very crowded space as there are at least a handful of companies for every new approach. Most Companies are OK with having competition because it gives them the impression there is safety in numbers, but we have a different approach: we have managed to be the only oncology company – that I am aware of– based on superantigen technology. So, in that, it is evident that we are not afraid to swim alone in the deep waters without a lifeguard because we know whatever sunken treasures we find belong solely to us; we have found a different approach that is worth fighting for.”

On his second strategy– thinking big– Nathan explained that as an oncology company with unique technology for cancer immunotherapy, NeoTX has world-renowned drug development capabilities but lacks drug discovery competency. So, their challenge is to bring the two together: drug discovery with breakthrough technology and drug development. “By putting the two together, we have a much bigger dream: an integrated company with assets and technologies that can drive innovation into the next decade and can make us a leading company for oncology treatment.”

“When I wake up every day, I tell myself to believe in the team and product and to lead the company by example. That is what gets us through each day, which has its own challenges, triumphs, and failures. But from these experiences, we learn, and we make improvements for next time.” He went on by saying that he knows from first-hand experience how challenging it is to hit the ground running on a startup, especially in biotech, with a lack of capital and data working in a constant loop against you. But when doubts fill your thoughts, you just have to think of your purpose: “Although it’s fun to see promising ideas get funded, it is far more satisfying to be part of the action and feel the thrill of seeing patients spared certain death because of something you are doing. When you see a patient with intractable cancer whose tumour is proliferating, which typically means he should have had less than 3 months to live, respond so well to the treatment from our technology, that after 2 years, he is still cancer free, you understand that what you are doing– the struggle to make this startup a success– is well worth it.”

No place like Israel

When we asked Nathan about his experiences here in Israel, as an entrepreneur and scientist, he gave a beautiful anecdote that sums up the spirit of Israel as the Startup Nation. He told us about a time during the COVID-19 pandemic when one of their partnered hospitals’ labs shut down. “When a patient in a trial receives our experimental drug, we need to take their blood and analyze it right away. During the peak of the pandemic, there was an instance where we unexpectedly couldn’t send it to the hospital we normally work with, so we were frantically trying to find a solution. We were able to find another unrelated hospital with a lab willing to volunteer to do the testing and a taxi driver who was patient enough to fetch it from the hospital and drive it to that lab which was in a completely different city. Such a chain of events would happen anywhere else in the world and is a true testament to our great nation.”

NeoTX was founded in 2015 by Asher Nathan (CEO), Ramona Lloyd Ph.D. (VP Regulatory), Marcel Rozencweig MD (President, Former Chief Medical Officer), Roger Kornberg Ph.D. (Chairman of the Board, Former Chief Scientist) and Robert Harow (Chief Financial Officer, Chief Operating Officer). To date, they have raised over $80 million. They are headquartered in Rehovot, Israel, with 50 employees worldwide.

Credit: GeekTime

Categories
News

NeoTX Featured in Israel21c

New cancer treatment fools the immune system to attack

NeoTX, whose team includes several Nobel laureates, is testing a cancer-fighting approach that uses bacteria to bait the immune system into an attack.

By Brian Blum JULY 5, 2022, 12:40 PM

Immunotherapy holds perhaps the greatest promise for fighting cancer in the 21st century. Rather than bombarding the body with toxic chemicals, as in chemotherapy, immunotherapy utilizes the immune system to neutralize malignant tumors.

The only problem: It only works in about 20 percent of patients with solid tumors.

The reason is straightforward, but still represents a vexing roadblock for cancer researchers: Tumors are not an infection coming from outside but an internal malfunction of the body’s own cells, which begin to replicate out of control.

“Cancer looks like us. It’s hard for the immune system to identify,” explains Dr. Asher Nathan, CEO of NeoTX, a Rehovot-based startup developing a novel way of knocking out tumors – by coating them in bacteria.

“Unlike with cancer, our bodies are finely tuned to attack bacteria,” Nathan says. “Bacteria is a billion years old. Our immune systems have had a long time to figure out how to effectively neutralize bacterial infections. That’s why you don’t wake up in the morning with a cold and think, ‘I’m going to die.’”

Cancer, of course, is a very different story. Compared with bacteria, “cancerous tumors are like the new kid on the block,” Nathan notes.

NeoTX is not Nathan’s first foray into medical technology; after immigrating to Israel 40 years ago from Chicago, he founded IntelliGene and EvoRX, two biotech companies formed around technologies he invented.

For NeoTX, Nathan identified and licensed a drug developed by the Swedish company Active Biotech called naptumomab estafenatox (NAP).

NAP is composed of two proteins: a genetically modified “superantigen” and an antibody that latches onto a tumor via a molecule called 5T4 found primarily on tumors.

A superantigen is a bacterial derivative that elicits a strong antibacterial immune response. NeoTX calls its technology “Tumor-Targeted Superantigen” or TTS.

Once NAP’s 5T4 antibody has attached itself to a tumor, the superantigen “reprograms” the immune system to mount an antibacterial response against the bacteria as well as the tumor.

“The concept behind this drug is, let’s coat the tumor with a bacterial molecule so that the immune system will go into ‘Defcon 1’ and attack the tumor as if it’s bacteria,” Nathan says.

The secret weapon

Once the immune system knows what to look for, it sends in the body’s secret weapon: killer T-cells.

The T-cells identify the bacteria-coated tumors, then start to create an army of cells primed to attack any superantigens they find. Nathan recommends the video below to see how T-cells work; they “grope around like a blind robot” and after hitting a superantigen, punch a hole in the cell … then insert a molecule that causes the cell to explode.”

It’s a fine balance. When fighting a bacterial infection, “the body can go crazy,” Nathan notes. “You can get a high fever that exhausts the immune system. That’s how the bacteria continue to fight. We genetically engineered our superantigen to be safer. It doesn’t generate as strong a response, but it still creates a very powerful immune reaction.”

Targeting bacteria is smart for another reason: Part of how tumors succeed in evading the body’s defenses is by releasing chemicals that weaken the immune response.

“Anything we do nearby the tumor becomes problematic,” Nathan says. But with NAP, “the tumor-killing T-cells are created far from the immune-suppressed tumor site.” Only then do they begin their journey to seek out and destroy the tumors.

Moreover, when the immune system encounters a superantigen bound to a tumor, it modifies the suppressive micro-environment around the tumor so that the body’s natural defenses are better able to kill it.

“This creates a natural, holistic and profound immune response,” Nathan says.

Reboots the immune system

But the best may be yet to come.

“When we’ve tested this drug in animals, we find that even when you try to reintroduce cancers into, say, a mouse that’s been cured by the technology, it doesn’t stick,” Nathan says.

“None of the mice that were ‘rechallenged’ got cancer again. The drug ‘wakes up’ the immune system – at least in mice – and we don’t need any more drug.”

Nathan likens it to the reboot function on a computer. “The drug reboots the immune system so it can do what it natively needs to do – remove the suppressive environment and kill as many tumor cells as possible. Then, the T-cells can go after more targets.”

NeoTX’s bacterial coating approach is currently in a Phase I trial in Israel and, based on encouraging results, has begun a Phase 2 trial in the United States with 30 patients.

One patient has non-small cell lung cancer that had metastasized to the liver. “That’s a death sentence, usually within four months,” Nathan says. The patient received NeoTX’s drug over a decade ago (prior to it being licensed from Active Biotech). “She lived for 11 years and died of something else, not her cancer.”

NAP plays particularly well with checkpoint inhibitors, another type of cancer treatment that aims to tamp down “checkpoints” created by the cancer that essentially trick the T-cells into thinking the tumor is a friend.

“It’s like a secret handshake in a college fraternity,” Nathan quips.

If the handshake were inhibited, so to speak, the T-cells would see the tumor for what it is – very much not a friend – and could attack. Combining NAP with a checkpoint inhibitor “allows our drug to kill more tumor cells,” Nathan says.

AstraZeneca collaboration

Pharma giant AstraZeneca is collaborating with NeoTX on the former’s own checkpoint inhibitor technology. The hope is that patients who don’t normally respond will have greater success in beating back their cancers.

Developing and commercializing any new drug can take up to 15 years and many millions of dollars. NeoTX has raised around $80 million so far. Nathan is optimistic that if NAP passes Phase 2 and 3 trials, it could hit the market as early as 2027.

While the technology has so far been tested on solid lung, esophageal and urethral cancer tumors, patients with blood cancer such as lymphoma and leukemia could benefit, too – in particular those who are candidates for CAR-T, a promising treatment that involves removing T-cells from a patient, engineering them for maximum killing ability in a lab, then reinjecting them.

CAR-T, a form of immunotherapy, tends to work well for blood cancers but poorly for solid tumors. That’s another aim for NeoTX – to provide a pharmaceutical complement that will allow CAR-T to be effective outside the blood cancer domain.

Immunotherapy has become a crowded field. “If you look at all the companies that are trying to elicit an immune system response, there are probably 1,000 out there. But for the specific mechanism we’re trying, it’s zero,” Nathan notes.

“One of our investors said to us, ‘You’re either geniuses or you’re crazy.’ I replied, ‘What makes you think it’s one or the other?’”

NeoTX has no shortage of geniuses. Roger Kornberg, the 2006 winner of the Nobel Prize in chemistry, is the company’s chief scientist (as well as a long-time collaborator with Nathan in his previous endeavors).

Michael Levitt and Arieh Warshel, who shared a Nobel in chemistry in 2013, are advisers. Dr. Marcel Rozencweig, a medical oncologist and 18-year veteran of pharma company Bristol Myers Squibb, where he was head of global oncology, is NeoTX’s president.

Recently, the head of global clinical oncology at Bayer pharmaceuticals, Dr. Scott Fields, joined NeoTX as chief medical officer.

“It is extremely rare that someone as high up as Scott Fields would leave pharma to work in such a small company,” Nathan tells ISRAEL21c. “It is even more rare that he would come to a company based in Israel.”

Cancer, sadly, isn’t going away anytime soon. “The average person develops around five cancerous or pre-cancerous cells a day,” Nathan notes.

“Our bodies are very efficient at killing, such that most people don’t get a new cancer every day. Our drug could level the playing field so the body can do what it’s meant to.”

Credit: Israel21c

Categories
Press Releases

NeoTX announces successful first stage completion of its Phase 2a clinical trial of naptumomab estafenatox (NAP), in combination with docetaxel in advanced non-small cell lung cancer (NSCLC)

REHOVOT, ISRAEL- June 1, 2022  

NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology drug development company, announced today the successful completion of the first stage of a Simon 2 stage Phase 2a clinical trial of naptumomab estafenatox (NAP), in combination with docetaxel in patients with advanced non-small cell lung cancer (NSCLC) who have been previously treated with chemotherapy and checkpoint inhibitors (CPIs). The patients were treated with NAP (10 μg/kg/day x 4, days 1-4) and with docetaxel 75mg/m2, on day 5. The first stage of this trial required a minimum of two responses out of ten patients and the second stage is now enrolling.

 “These early observations are encouraging as patients with advanced disease previously treated with chemotherapy and checkpoint inhibitors have limited treatment options and new alternatives are needed. In addition, this clinical milestone occurs just as the acquisition of InterX has been recently completed, adding a computer-aided drug discovery arm (CADD) to the pre-clinical and clinical capabilities of NeoTX. So, this has been a crucial time for us” said Asher Nathan, CEO of NeoTX. “NeoTX’s drug discovery capabilities are strengthened by a world-class team that includes three Nobel Laureates. InterX technologies have the potential to significantly increase the speed of drug discovery. InterX also provided a pipeline that includes an oral PD-L1 inhibitor, which aligns with our current development plan of investigating NAP in combination with CPIs in various indications.”

 

About NeoTX

NeoTX is a clinical-stage company developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an immune response. The company’s lead TTS molecule, naptumomab estafenatox (NAP) is currently in clinical development for advanced solid tumors: NCT03983954, and NCT04880863. NeoTX’s computer aided drug discovery (CADD) subsidiary utilizes groundbreaking technology to dramatically decrease drug discovery times. . For more information, please visit www.neotx.com

 

Media Contact:
Aviram Uzi
Head of PR and Communications
Gelbart-Kahana Investor Relations
aviram@gk-biz.com
+972-525329103

Investor Contact:
Robert Harow, CFOO
NeoTX Therapeutics Ltd
robert@neotx.com
+1 609-718-2305 x204
+972 3 912 5853 x204

Categories
Press Releases

NEOTX ACQUIRES INTERX, ADDS WORLD CLASS DISCOVERY ARM

REHOVOT and TEL AVIV, ISRAEL; MENLO PARK and BERKELEY, CALIFORNIA.  — May 12, 2022 – NeoTX announced today the acquisition of InterX. InterX, is a drug discovery company utilizing advanced proprietary tools of biomolecular computation for the discovery and design of novel therapeutic molecules based on Nobel Prize Laureate Prof Michael Levitt’s discoveries. These tools allow a detailed quantum mechanical process assessment of biochemical interactions resulting in faster, more accurate and efficient drug discovery. In addition to the discovery engine, this acquisition also comes with a pipeline of early drugs. “We are excited to be expanding NeoTX capabilities to include a suite of proprietary drug discovery technologies. InterX is a world class team that includes three Nobel Laureates who have developed technologies that have the potential to increase the speed of drug discovery. These technologies augment traditional Computer Assisted Drug Discovery (CADD) and are designed to replace much of the typical synthesis and testing cycles that are needed after obtaining results from the traditional CADD process, while potentially saving three-plus years of the typical drug discovery timeline” said CEO, Asher Nathan. “InterX’s technology is the most advanced in the industry, and when combined with the development expertise of NeoTX, we will be able to advance best-in-class drug candidates, increase the value of our pipeline, and strive to contribute to improvement of quality of life within society,” said Nobel Prize Laureate Prof. Roger Kornberg, Chief Scientist of NeoTX and cofounder of InterX. InterX will benefit from the experience and infrastructure of NeoTX while maintaining a culture of innovation and creativity. Post-merger, Prof. Kornberg has also assumed the role of Chairman of the Board of NeoTX. About NeoTX NeoTX is a clinical-stage company developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an immune response. The company’s lead TTS molecule, naptumomab estafenatox (NAP) is currently in clinical development for advanced solid tumors. For more information, please visit www.neotx.com About InterX InterX is a drug development company, based in the United States and Israel, which is revolutionizing biomolecular computation of chemical and biological systems. The company aims to achieve robust and accurate prediction of molecular and ensemble properties of biological systems using computational methods. InterX is led by Nobel Prize-winning scientist Roger Kornberg. For more information, please visit www.interx.dev   Media Contact: Aviram Uzi Head of PR and Communications Gelbart-Kahana Investor Relations aviram@gk-biz.com +972-525329103   Investor Contact: Robert Harow, CFOO NeoTX Therapeutics Ltd robert@neotx.com 609-718-2305 x204  
Categories
News

NeoTX Featured in the Jerusalem Post

NeoTX Therapeutics in the JPost:

https://www.jpost.com/health-and-wellness/article-701906

 

 

Categories
Press Releases

NeoTX Therapeutics promotes Marcel Rozencweig, M.D., to President and welcomes Scott Z. Fields, M.D., as new Chief Medical Officer

Rehovot, Israel — Jan 31, 2022 – NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology company, announced the promotion of current CMO, Marcel Rozencweig, M.D., to President and the appointment of Scott Z. Fields, M.D., as the new chief medical officer, effective tomorrow, Feb 01, 2022.   Dr. Fields brings more than 30 years of experience in clinical drug development and has been previously the Senior Vice President and Pharmaceutical Development Head, Oncology at Bayer Pharmaceuticals (OTC: BAYRY). 645382

“We are thrilled that Marcel will be the President to lead NeoTX in its next chapter of growth and success.  He has been a key part of NeoTX growth since its inception and, in his new role as President, will help to accelerate growth and expand strategic industry partnerships” said Asher Nathan, Ph.D., chief executive officer of NeoTX.

“I am very pleased and looking forward to leading, as President, in NeoTX’s advancement” said Dr. Rozencweig.  “Additionally, as a founding member of NeoTX, it gives me great pleasure to welcome Dr. Fields to our leadership team.”

“We, at NeoTX, are delighted that Scott is bringing his strong industry and operational leadership, which will prove valuable for our clinical development and registration strategies.  His broad experience in oncology drug development, with over a dozen drug approvals, is an excellent fit with our vision.” said Asher Nathan, Ph.D., chief executive officer of NeoTX.

“I’m thrilled to join NeoTX at this time of important growth and evolution of the company,” said Dr. Fields. “Together with our experienced leadership team, I look forward to helping the company accelerate the development of our pipeline and bring innovative new medicines to patients.”

As Global Head of Development for Oncology at Bayer Pharmaceuticals, Dr. Fields was responsible for early and late-stage development including several novel oncology medicines across the platforms for targeted therapies/precision medicine, antibody drug/alpha radiation conjugates and novel Immuno-Oncology agents. His group was responsible for the development and global registration of Darolutamide – a next generation androgen receptor inhibitor for prostate cancer and with partner Loxo, for Larotrectinb – a tissue agnostic NTRK inhibitor.  He was also responsible for the Oncology Operations, Project Management, Regulatory, Biomarkers, Biostatistics and Medical Writing groups. Prior to his position at Bayer, Dr. Fields held senior positions at Vertex Pharmaceuticals (NASDAQ: VRTX), SmithKline Beecham (NYSE: GSK), Amgen (NASDAQ: AMGN), Eisai (OTC: ESALY), and Arno Therapeutics (OTC: ARNI) and helped bring over a dozen drugs to market. He also practiced oncology/hematology and transplant medicine in academic settings.  Dr. Fields received his medical degree from SUNY Downstate Medical Center in New York, followed by training in internal medicine, hematology and oncology at Columbia University Medical Center.

 

 

About NeoTX

NeoTX is a clinical-stage immuno-oncology company which is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an immune response. The company’s lead TTS molecule, naptumomab estafenatox (NAP) is currently in clinical development for non-small cell lung cancer and other solid tumors. For more information, please visit www.neotx.com

 

Media Contact:
Aviram Uzi

Head of PR and Communications

Gelbart-Kahana Investor Relations

aviram@gk-biz.com

+972-525329103

 

Investor Contact:
Robert Harow, CFOO
NeoTX Therapeutics Ltd
robert@neotx.com 
609-718-2305 x204

 

Categories
Press Releases

Data on Naptumomab Estafenatox (NAP) Enhancing CAR-T cells Potency Presented by NeoTX at SITC 2021 Annual Meeting.

Rehovot, Israel — November 30, 2021 – NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology company, announced that the preclinical data on naptumomab estafenatox (NAP) enhancing the potency of CAR-T cells was presented on Nov 12th at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting at the Walter E. Washington Convention Center, Washington D.C.

Clinical CAR-T therapy currently has limited efficacy against solid tumors due to low trafficking to the tumor, limited cell expansion in patients, tumor antigen heterogeneity, and an immunosuppressive microenvironment. NeoTX presented data that shows that NAP generates more potent CAR-T cells and acts synergistically against tumor cell lines in vitro. NAP is a fusion protein that consists of genetically engineered Superantigens (Sag) linked to Fragment antigen-binding (Fab) moieties directed to tumor-associated antigens, turns “cold tumors hot” and, in preclinical models, can lead to long-term memory responses.

The ability of NAP administration to activate T cells outside of the immunosuppressive microenvironment, promote T cell infiltration into the tumor and induce long-term memory responses strongly suggests that the combination of CAR-T cells with NAP may overcome the limited effect of CAR-T therapy against solid tumors. To access the presented poster, please click here.

 

About NeoTX

NeoTX is a clinical-stage immuno-oncology company which is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an immune response. The company’s lead TTS molecule, naptumomab estafenatox (NAP) is currently in clinical development for non-small cell lung cancer and other solid tumors. For more information, please visit www.neotx.com

 

Media Contact:
Aviram Uzi
Head of PR and Communications
Gelbart-Kahana Investor Relations
aviram@gk-biz.com
+972-525329103

Investor Contact:
Robert Harow, CFOO
NeoTX Therapeutics Ltd
robert@neotx.com 
609-718-2305 x204

Categories
Press Releases

NeoTX Therapeutics to Present at the Society for Immunotherapy of Cancer’s 36th Annual Meeting

REHOVOT, Israel – November 9, 2021 – NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology company, today announced a presentation on the company’s lead program, naptumomab estafenatox (NAP), at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting being held November 10-14, 2021 at the Walter E. Washington convention Center, Washington D.C.  The poster presentation will highlight preclinical data demonstrating that NAP enhances CAR-T cells potency and can boost CAR-T efficacy against solid tumors.

Details on the poster presentation are as follows:

  • Title: Tumor Targeted Superantigen (TTS), Naptumomab Estafenatox (NAP), enhances CAR-T cells potency and can boost CAR-T efficacy against solid tumors
  • Abstract Number: 576 (ePoster)
  • Lead Author: Yael Sagi, Ph.D.
  • Category: Combination Immunotherapies
  • Date & Time: The ePoster will be on display on the SITC 2021 virtual meeting platform from 7 a.m. EST on Friday, Nov. 12, 2021 until the virtual meeting platform is closed on Jan. 9, 2022.

About NeoTX

NeoTX is a clinical-stage immuno-oncology company which is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an immune response. The company’s lead TTS molecule, naptumomab estafenatox (NAP) is currently in clinical development for advanced solid tumors. For more information, please visit www.neotx.com

Media Contact:
Aviram Uzi
Head of PR and Communications
Gelbart-Kahana Investor Relations
aviram@gk-biz.com
+972-525329103

Investor Contact:
Robert Harow, CFOO
NeoTX Therapeutics Ltd
robert@neotx.com 
609-718-2305 x204

Categories
Press Releases

NeoTX Announces First Patient Enrolled In Phase 2a Clinical Trial Of Naptumomab Estafenatox (NAP), Its Lead Tumor Targeted Superantigen (TTS) Candidate, In Combination With Docetaxel In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

REHOVOT, Israel – October 20, 2021 – NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology company, announced today that the first patient has been enrolled in the company’s phase 2a clinical trial of naptumomab estafenatox (NAP), its lead Tumor Targeted Superantigen (TTS) candidate, in combination with docetaxel in patients with advanced non-small cell lung cancer (NSCLC).

 “Dosing of the first patient in this phase 2 trial represents a crucial step forward for the clinical advancement of NAP” said Asher Nathan, Ph.D., chief executive officer of Neo TX. “This trial is based on promising phase 1 data. NSCLC is one of the deadliest cancers, and we are looking forward to evaluating NAP in this setting”.

 The phase 2a, open label trial in the US, will assess NAP in combination with docetaxel in patients who had been previously treated with checkpoint inhibitors and have advanced or metastatic NSCLC.  The primary endpoint is objective response rate as measured by RECIST 1.1 criteria.  The trial will also evaluate safety, duration of response, progression free survival, overall survival, pharmacokinetics, and pharmacodynamics. For more information about the trial, visit https://clinicaltrials.gov/ct2/show/NCT04880863

 

About NeoTX

NeoTX is a clinical-stage immuno-oncology company which is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an immune response. The company’s lead TTS molecule, naptumomab estafenatox (NAP) is currently in clinical development for advanced solid tumors. For more information, please visit www.neotx.com

 

Media Contact:
Aviram Uzi
Head of PR and Communications
Gelbart-Kahana Investor Relations
aviram@gk-biz.com
+972-525329103

Investor Contact:
Robert Harow, CFOO
NeoTX Therapeutics Ltd
robert@neotx.com
609- 718-2305

Categories
Press Releases

Key Opinion Leader Webinar on Overcoming Check Point Inhibitor Resistance and Update on NeoTX TTS Platform

REHOVOT, Israel —July 14, 2021 – NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology company, hosted a key opinion leader (KOL) webinar on overcoming checkpoint inhibitor resistance on Wednesday, July 14, 2021.

The webinar featured a presentation by KOL Mario Sznol, MD, Yale Cancer Center, who discussed New Frontiers for Checkpoint Inhibitors in Immuno-Oncology. NeoTX’s management gave an update on their Tumor Targeted Superantigen (TTS) platform’s lead candidate, naptumomab estafenatox (NAP) in overcoming resistance. NAP is being evaluated in combination with chemotherapy, checkpoint inhibitors and CAR T. Dr. Sznol and NeoTX management answered questions following the formal presentations.

To watch the webinar recording, please click here.

 About NeoTX

NeoTX is a clinical-stage immuno-oncology company which is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an effective response. The company’s lead TTS molecule, naptumomab estafenatox (NAP) is currently in clinical development for advanced solid tumors. For more information,

Media Contact:
Cait Williamson, Ph.D.
LifeSci Communications
(646) 751-4366
cait@lifescicomms.com